New Data Highlights Potential of Erbitux in Metastatic Colorectal Cancer Treatment

Strategic Insights -

The American Society of Clinical Oncology (ASCO) 2005 meeting unveiled new data from three clinical trials demonstrating the effectiveness of Erbitux (cetuximab) in the first-line treatment of metastatic colorectal cancer (mCRC). The preliminary findings revealed a consistently high response rate, leading to an increased potential for surgical intervention in patients whose metastases were previously inoperable. These results reinforce the potential of Erbitux to not only delay time to disease progression but also to shrink metastases to allow surgical resection with curative intent.

Key Takeaways:

  • Erbitux in combination with the FOLFOX-4 regimen showed an overall response rate of 81%, delaying time to disease progression to 12.3 months, with 52% of patients free from disease progression at 12 months.
  • The ACROBAT study demonstrated an 81% overall response rate, with 21% of patients with previously unresectable metastases able to undergo surgery.
  • In the Phase I/II studies, Erbitux showed a favorable safety profile with few additional side effects compared to standard chemotherapy.
  • The BOND study demonstrated that Erbitux maintained its response rate and overall survival benefit in the treatment of mCRC.
  • Erbitux has already obtained market authorization in several countries, including the US, Switzerland, Mexico, and the European Union.
  • In the US, Argentina, Chile, Mexico, Peru, Singapore, and Australia, Erbitux is also approved for single-agent usage.
  • The company, Merck KGaA, is committed to the advancement of oncology treatment and is investigating novel therapies in highly targeted areas.

Statistics:

  • 81% overall response rate for Erbitux in combination with FOLFOX-4 regimen
  • 12.3 months delayed time to disease progression
  • 52% of patients free from disease progression at 12 months
  • 21% of patients with previously unresectable metastases able to undergo surgery
  • 5% of patients experience hypersensitivity reactions during treatment with Erbitux

Sources:

  • Diaz Rubio E et al., Presented at ASCO, Orlando, Florida, 2005: abstr 3535.
  • Folprecht G et al., Proceedings ASCO, Orlando, Florida, 2005: abstr 3640.
  • Seufferlein T et al., Proceedings ASCO, Orlando, Florida, 2005: abstr 3644.
  • Mineo TC et al., J Am Coll Surg 2003; 197 :386-391.
  • Giacchetti S et al., Ann Oncol 1999; 10 (6): 663-9.
  • Cunningham D et al., N Engl J Med 2004; 22; 351(4): 337-45.
  • Saltz L et al., Proc Am Soc Clin Oncol 2001; Vol 20: abstr 7.
  • Saltz L et al., J Clin Oncol 2004; 22 (7): 1-8.